More than 85 small molecule protein degraders are currently being evaluated for the treatment of various disease indications, BY Roots Analysis

The concept of targeted protein degradation presents revolutionary drug development opportunities and is anticipated to bring about a paradigm shift in modern healthcare. The first targeted protein degrader, called proteolysis targeting chimera (PROTAC), was developed about a decade ago. Presently, a variety of other such chemical entities and molecular glues are under investigation. In fact, certain pipeline candidates are already in the mid to late-phase trials and are anticipated to soon enter the market.

• A detailed assessment of the current market landscape of targeted protein degradation-based therapeutics, providing information on drug / therapy developer(s) (such as year of establishment, company size and location of headquarters), clinical study sponsor(s) and collaborator(s), type of protein degrader (degronimids, ENDTACs, epichaperome inhibitors, hydrophobic tags, IMiDs, LYTACs, molecular glues, PHOTACs, PROTACs, protein homeostatic modulators, SARDs, SERDs, SNIPERs, and specific BET and DUB inhibitors), phase of development (clinical, preclinical, and discovery stage) of product candidates, target indication(s), key therapeutic area(s), type of target protein(s), target enzyme(s) (if available), target signaling pathway (if available), mechanism of action (if available), type of therapy (monotherapy and combination therapy), route of administration (oral, intravenous and others), and information on special drug designations (if any). In addition, the chapter highlights the various technology platforms that are being actively used for the development of targeted protein degraders.
• Elaborate profiles of key players that are engaged in the development of targeted protein degraders (shortlisted on the basis of phase of development of pipeline products), featuring a brief overview of the company, its financial information (if available), detailed descriptions of their respective lead drug candidates, and an informed future outlook. Additionally, each drug profile features information on the type of drug, route of administration, target indications, current status of development and a brief summary of its developmental history.

Brief tabulated profiles of industry players (shortlisted on the basis of the number of pipeline products), featuring details on the innovator company (such as year of establishment, location of headquarters, number of employees, and key members of the executive team), recent developments, along with descriptions of their respective drug candidates

 

To order this 330+ page report, which features 130+ figures and 145+ tables, please visit  https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html

 

 

The USD 3.6 billion (by 2030) financial opportunity within the target protein degradation market has been analyzed across the following segments:

• Type of payment of licensing agreements
• Upfront payments
• Milestone payments

 

• Type of protein degrader
• Degronimids
• PROTACs
• SARDs / SERDs
• Specific BET and DUB inhibitors
• Other protein degraders

 

• Therapeutic area
• Neurodegenerative disorders
• Oncological disorders
• Other therapeutic areas

 

• Route of administration
• Oral
• Intravenous
• Other routes

 

• Key geographical region
• North America
• Europe
• Asia-Pacific

 

The Targeted Protein Degradation Market: Focus on Therapeutics and Technology Platforms (based on Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags, IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs, Protein Homeostatic Modulators, SARDs, SERDs, SNIPERs, and Specific BET and DUB Inhibitors), 2020-2030 report features the following companies, which we identified to be key players in this domain:

• Arvinas
• Captor Therapeutics
• Celgene
• Genetech
• Kymera Therapeutics
• Mission Therapeutics
• Progenra
• Radius Health
• Sanofi Genzyme
• Zenopharm

 

Table of Contents

 

1. Preface
2. 
   Executive Summary
3. 
   Introduction
    
4. Current Market Landscape
    
5. Company Profiles
    
6. Clinical Trial Analysis
    
7. KOL Analysis
    
8. Publication Analysis
    
9. Funding and Investment Analysis
    
10. Partnerships and Collaborations
     
11. Market Sizing and Opportunity Analysis
     
12. Executive Insights

 

1. Concluding Remarks

 

1. Appendix 1: Tabulated Data

 

1. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]